Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
Conditions: Melanoma; Melanoma Stage III; Melanoma Stage IV; Unresectable Melanoma Interventions: Diagnostic Test: 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Sponsors: University of Wisconsin, Madison Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2024 Category: Research Source Type: clinical trials
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: HER3 Monoclonal antibodies; Drug: Cetuximab injection; Other: Placebo Sponsors: Shanghai Institute Of Biological Products Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
Conditions: Melanoma Interventions: Drug: Defactinib; Drug: Avutometinib; Drug: Encorafenib Sponsors: University of Utah; Verastem, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: KC1036; Drug: Irinotecan; Drug: Docetaxel; Drug: S-1 Sponsors: Beijing Konruns Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma
Conditions: HNSCC; Adults Interventions: Biological: GT201 in combination with PD-1 inhibitors Sponsors: Grit Biotechnology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
PPIO-005 The Relationship Between Different Nutritional Pathways and Tumor Outcomes After Minimally Invasive Esophagectomy
Conditions: Esophageal Squamous Cell Carcinoma Sponsors: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
Conditions: Metastatic Esophageal Squamous Cell Carcinoma Interventions: Drug: Chemotherapy combined with immunotherapy; Radiation: radiotherapy Sponsors: Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital and Research Institute; Henan Cancer Hospital; Shanxi Province Cancer Hospital; Hunan Cancer Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
Conditions: Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IIID Melanoma Interventions: Biological: LN-144; Drug: Cyclophosphamide; Drug: Mesna; Drug: Fludarabine; Biological: Interleukin-2 (IL-2); Drug: Pembrolizumab Sponsors: James Isaacs, MD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: sintilimab Sponsors: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Local Therapy for Oligometastatic Esophageal Squamous Cell Cancer Patients Treated With PD-1 Inhibitor: a Prospective, Randomized, Phase III Clinical Trial.
Conditions: Esophageal Squamous Cell Carcinoma; Oligometastatic Disease; Radiotherapy Interventions: Combination Product: PD-1 inhibitor+/- chemotherapy combined with local therapy; Drug: PD-1 inhibitor+/- chemotherapy alone Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer
Conditions: Esophageal Squamous Cell Carcinoma; Chemoradiotherapy; Initial Inoperable Interventions: Other: regular chemoradiotherapy Sponsors: Anhui Provincial Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Clinical Study of GT201 Combined With PD-1 Inhibitor in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma
Conditions: HNSCC; Adults Interventions: Biological: GT201 in combination with PD-1 inhibitors Sponsors: Grit Biotechnology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Pembrolizumab in Adult Participants With Resectable Stage 3 or 4 Melanoma
Conditions: Melanoma Interventions: Drug: pembrolizumab; Drug: fianlimab HD; Drug: cemiplimab; Drug: fianlimab LD; Drug: Placebo Sponsors: Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Holistic Needs Assessments in Patients With Melanoma
Conditions: Melanoma; Unsatisfied Needs Interventions: Other: Holistic needs assessment based on the use of patient-reported outcome measures Sponsors: University of Surrey Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2024 Category: Research Source Type: clinical trials
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma Interventions: Drug: S-1; Drug: Toripalimab; Radiation: Intensity-modulated radiotherapy Sponsors: Sun Yat-sen University; Nanfang Hospital, Southern Medical University; Zhujiang Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Xiangya Hospital of Central South University; Wuhan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 1, 2024 Category: Research Source Type: clinical trials
